Skip to content

Savara SVRA Debt Issuance Proceeds

Debt Issuance Proceeds at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$134.67M
LQD
Liquidia CorporationLQDA
$0-100%
TG Therapeutics logo
TG TherapeuticsTGTX
$747.66M
AdaptHealth logo
AdaptHealthAHCO
$100M
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$400M
Moderna logo
ModernaMRNA
$150M

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+236%
Enterprise value$1.19B+224%
P/S4,648.7×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfLongTermDebt.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's debt issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's debt issuance proceeds?
Savara (SVRA) reported debt issuance proceeds of $29.6M in Q1 2025.
What does debt issuance proceeds mean?
Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.